Publications by authors named "A J Herline"
Objective: To determine the disease-free survival (DFS) and recurrence after the treatment of patients with rectal cancer with open (OPEN) or laparoscopic (LAP) resection.
Background: This randomized clinical trial (ACOSOG [Alliance] Z6051), performed between 2008 and 2013, compared LAP and OPEN resection of stage II/III rectal cancer, within 12 cm of the anal verge (T1-3, N0-2, M0) in patients who received neoadjuvant chemoradiotherapy. The rectum and mesorectum were resected using open instruments for rectal dissection (included hybrid hand-assisted laparoscopic) or with laparoscopic instruments under pneumoperitoneum.
Colorectal Cancer Screening and Surveillance in Individuals at Increased Risk.
Am Fam Physician
January 2018
Individuals at increased risk of developing colorectal cancer include those with a personal or family history of advanced adenomas or colorectal cancer, a personal history of inflammatory bowel disease, or genetic polyposis syndromes. In general, these persons should undergo more frequent or earlier testing than individuals at average risk. Individuals who have a first-degree relative with colorectal cancer or advanced adenoma diagnosed before 60 years of age or two first-degree relatives diagnosed at any age should be advised to start screening colonoscopy at 40 years of age or 10 years younger than the earliest diagnosis in their family, whichever comes first.
View Article and Find Full Text PDFCollege-aged males are at high risk for human papillomavirus (HPV); however, vaccination rates remain low, suggesting minimal HPV knowledge. Therefore, an educational intervention was developed and implemented to determine if an increase in HPV knowledge, perceived HPV risk, intention and perceived self-efficacy to obtain the vaccine, and vaccination rates were observed.
View Article and Find Full Text PDFArticle Synopsis
- Distinguishing between Crohn's colitis and ulcerative colitis is crucial because misdiagnosis leads to indeterminate colitis, affecting appropriate treatment options for about 30% of inflammatory bowel disease (IBD) patients.
- Researchers assessed the expression of Human α-Defensin-5 in patients using various techniques and found significantly higher levels in Crohn's colitis compared to other types, with a 96% positive predictive value for differentiating it from ulcerative colitis.
- The study demonstrates that Human α-Defensin-5 can help accurately classify indeterminate colitis patients, showing that those with high levels are likely to have Crohn's disease, while low levels indicate ulcerative colitis.